gsk201202206k5.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 

 
 
 


 

 
 
Notification of Transactions of
Directors and Persons Discharging Managerial Responsibility
 
Vesting of conditional share awards made under
the GlaxoSmithKline Share Value Plan
 
This notification sets out the vesting of share awards made in 2009 under the GlaxoSmithKline Share Value Plan (SVP), which is conditional on continued employment with the GlaxoSmithKline group.
 
The three-year vesting period for the 2009 SVP awards, which commenced on 17 February 2009, came to an end on 16 February 2012. The vesting of the SVP awards on 17 February 2012 made to individuals who have subsequently been appointed Persons Discharging Managerial Responsibility (PDMR), are given in the table below.
 
 
 
Name of PDMR
Number of shares vested
Mr P Thomson
 1730
Mrs V A Whyte
 1730
 
The Company and PDMRs were advised of these transactions on 20 February 2012.
 
The closing middle market price of an Ordinary share of GlaxoSmithKline plc on 17 February 2012 was £14.14.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
V A Whyte
Company Secretary
 
20 February 2012
 

 

 
 
 


SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 20, 2012
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc